### Ultrasonic Texture Analysis for Acute Myocardial Infarction Risk Stratification: A Pilot Study

Quincy A. Hathaway, MD, PhD<sup>1,2</sup>\*, Ankush D. Jamthikar, PhD<sup>1</sup>\*, Bernard R. Chaitman, MD<sup>3</sup>, Jeffery Carson, MD, MPH<sup>4</sup>, Naveena Yanamala, MS, PhD<sup>1</sup>, Partho P. Sengupta, MD, DM<sup>1</sup>

<sup>1</sup>Division of Cardiovascular Disease and Hypertension, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

<sup>2</sup>Department of Medical Education, West Virginia University School of Medicine, Morgantown, WV, USA.

<sup>3</sup> St. Louis University School of Medicine, St. Louis, MO, USA

<sup>4</sup>Division of General Internal Medicine, Department of Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick

Running Title: Ultrasonic Texture and Myocardial Infarction Risk Stratification

\*Provided equal contribution to the work

### **Corresponding Author**

Partho P. Sengupta, MD, DM, FACC, FASE Rutgers Robert Wood Johnson Medical School, Division of Cardiovascular Disease and Hypertension, 125 Patterson St, New Brunswick, NJ – 08901 Phone: (646) 531-2613 Email: <u>partho.sengupta@rutgers.edu</u>

Word Count: 3,672

### Abstract

**Background**: Current risk stratification tools for acute myocardial infarction (AMI) have limitations, particularly in predicting mortality. This study utilizes cardiac ultrasound radiomics (i.e., ultrasomics) to risk stratify AMI patients when predicting all-cause mortality.

**Methods**: The study included 197 patients: a) retrospective internal cohort (n=155) of non-ST-elevation myocardial infarction (n=63) and ST-elevation myocardial infarction (n=92) patients, and b) external cohort from the multicenter Door-To-Unload in STsegment-elevation myocardial infarction [DTU-STEMI] Pilot Trial (n=42). Echocardiography images of apical 2, 3, and 4-chamber were processed through an automated deep-learning pipeline to extract ultrasomic features. Unsupervised machine learning (topological data analysis) generated AMI clusters followed by a supervised classifier to generate individual predicted probabilities. Validation included assessing the incremental value of predicted probabilities over the Global Registry of Acute Coronary Events (GRACE) risk score 2.0 to predict 1-year all-cause mortality in the internal cohort and infarct size in the external cohort.

**Results**: Three phenogroups were identified: Cluster A (high-risk), Cluster B (intermediate-risk), and Cluster C (low-risk). Cluster A patients had decreased LV ejection fraction (P=0.004) and global longitudinal strain (P=0.027) and increased mortality at 1-year (log rank P=0.049). Ultrasomics features alone (C-Index: 0.74 vs. 0.70, P=0.039) and combined with global longitudinal strain (C-Index: 0.81 vs. 0.70, P<0.001) increased prediction of mortality beyond the GRACE 2.0 score. In the DTU-

STEMI clinical trial, Cluster A was associated with larger infarcts size (>10% LV mass, P=0.003), compared to remaining clusters.

**Conclusions**: Ultrasomics-based phenogroup clustering, augmented by TDA and supervised machine learning, provides a novel approach for AMI risk stratification.

Keywords: Topology; TDA; Semantic Segmentation; Ultrasomics; Machine Learning

### 1 Introduction

2 Globally, acute myocardial infarction (AMI) affects nearly 10% of people over 60 3 years of age (1). In the United States, the total annual cost of AMI was \$85 billion in 4 2016, with an estimated \$40 billion lost due to premature mortality in the preceding 5 decade (2). Unfortunately, despite the success of intervention and evolving guideline-6 directed treatment, AMI patients continue to have high morbidity and mortality (3). 7 Currently, clinicians use validated risk stratification scoring systems, such as the Global 8 Registry of Acute Coronary Events (GRACE) (4,5) and more recently the GRACE 2.0 9 score (6), to predict the 6-month and 1-year risk of all-cause mortality following AMI. 10 While guidelines have recommended using the GRACE score as the most robust model 11 for all acute coronary syndrome types (7-9), these scores were developed using clinical 12 trial data long before percutaneous interventions became routine. Moreover, GRACE 13 uses conventional statistical approaches (i.e., logistic regression) with fixed linear 14 assumptions on data behavior and limited variables, resulting in modest discrimination 15 (e.g., C-statistic range for predicting mortality:0.65-0.8) (5,9).

16 Artificial intelligence (AI) techniques have led to the development of novel 17 methods that includes subjecting images and other inputs to sophisticated algorithms to 18 capture complexity of human health and disease at the level of the individual (10). 19 These methods have achieved remarkable success, especially in disease classification 20 and risk assessments, in several image-based disciplines, such as dermatology, 21 aastroenterology, ophthalmology, oncology, and neuroradiology (10-16), including the 22 development of 'omics'-based decision support tools (17-21). The application of 23 radiomics to cardiac ultrasound (i.e., ultrasomics), may aid in risk stratification of

patients experiencing an AMI by extracting texture-based information from the myocardium. Moreover, the development of automated tools that integrate ultrasomics for AMI risk stratification addresses the existing gap in current guidelines which do not currently integrate cardiac imaging-based information in existing tools like GRACE 2.0 for estimating risk.

29 In the present study, we used a cluster-then-predict approach for AMI risk 30 stratification. We subjected cardiac ultrasomics information to topological data analysis 31 (TDA)—a robust method to create compressed representations of highly dimensional 32 data to create unique patient phenogroups (22). We illustrate that the ultrasomics 33 phenogroups can provide independent and incremental information to conventional 34 tools like GRACE 2.0 for augmenting 1-year mortality prediction in AMI patients. 35 Moreover, TDA can be effectively combined with machine learning and explainable AI 36 techniques. Accordingly, we also illustrate the ability to develop robust supervised 37 machine-learning algorithms on clustered patients, which can be applied to external 38 data for phenogroup prediction. Since infract size is strongly associated with all-cause 39 mortality in AMI (23), we used the Door-To-Unload in STEMI (DTU-STEMI) Pilot Trial 40 (24) as an external, prospective, multicenter clinical trial cohort to illustrate that the high-41 risk phenogroup had larger infarct size as observed on cardiac magnetic resonance 42 (CMR) imaging.

### 43 Materials and Methods

### 44 Study Population

For the internal validation dataset, we identified 155 AMI patients retrospectively from electronic medical record of Robert Wood Johnson University Hospital who were admitted over a 6-month period between January 2023 to July 2023. The Institutional Review Board (IRB) of Robert Wood Johnson University Hospital gave ethical approval for this work (#Pro2023001660).

This included 87 patients classified as having a NSTEMI (non-ST-elevation 50 51 myocardial infarction) and 121 as having a STEMI (ST-elevation myocardial infarction). 52 STEMI was classified per the Joint ESC/ACCF/AHA/WHF Task Force (25). Briefly, this 53 included ECG changes revealing 1) new ST-segment elevation in 2 contiguous leads 54 with greater than 0.1 mV in all leads, with the exception of V2 or V3, 2) new ST-55 segment elevation in leads V2-V3 greater than 0.2 mV (men > 40 years old), 0.25 mV 56 (men < 40 years old), or 0.15 mV (women), 3) Pre-existing left bundle branch block 57 were further evaluated using the Sgarbossa's criteria (26,27). Exclusion criteria included 58 (1) patients discharged to institutionalized care, (2) type 2-5 acute myocardial infarction 59 (AMI), (3) co-existing terminal illness such as cancer, (4) alternative diagnosis for 60 elevated cardiac troponin values (e.g. myocarditis, pericarditis, non-ischemic 61 cardiomyopathies, moderate-severe valvular heart disease), (5) pregnancy, and (6) 62 technically insufficient imaging for 2 of the following 3 views: apical 4 chamber (A4C), 63 apical 3 chamber (A3C), and apical 2 chamber (A2C). Of the 208 patients initially 64 enrolled, 53 patients were accordingly excluded from analysis, this included patients

with NSTEMI (n=24) and STEMI (n=29). We assessed the performance of the GRACE
2.0 score (6) with the primary outcome of all-cause mortality at one year.

67 For the external validation dataset, participants were recruited from a 68 prospective, multicenter, randomized DTU-STEMI pilot trial (24). We included 42 69 participants with CMR data in the current study. Briefly, patients were included in the original randomized pilot trial if they 1) were between 21 and 80 years of age and 2) 70 71 presented with 1-6 hours of chest pain with documented ST-segment elevation of ≥2 72 mm in  $\geq 2$  contiguous anterior leads or  $\geq 4$  mm total ST-segment deviation sum in the 73 anterior leads. Patients were excluded if they had prior AMI, coronary artery bypass 74 grafting surgery, out-of-hospital cardiac arrest requiring cardiopulmonary resuscitation, 75 cardiogenic shock, inability to undergo Impella CP insertion, fibrinolysis within 72 hours 76 of presentation, or contraindications to CMR imaging (24).

77 For the external validation study infarct size on CMR was used as the primary 78 end point. CMR-quantified infarct size was categorized as large (LGE mass accounting 79 for >10% of the total LV mass) or small (LGE mass accounts for ≤10% of the total LV 80 mass) (28,29). The details of the CMR protocol have been previously described (24). 81 Briefly, patients in the DTU-STEMI trial underwent standard CMR with steady-state free-82 precession sequence for LV ejection fraction, volumes, and mass analysis on days 3 to 83 5 and again on day 30 (±7 days). Delayed-enhancement imaging was performed using 84 2-dimensional segmented inversion-recovery sequence, 10 minutes after а 85 administration of routine extracellular gadolinium contrast (0.15 mmol/kg of body 86 weight). Infarct size was expressed as a percentage of total LV mass. A central core 87 laboratory (Duke Cardiovascular Magnetic Resonance Center, Durham, NC) qualified

participating sites, performed quality assessment on the images during the conduct of the study, and manually performed assessment of CMR parameters on deidentified images without knowledge or access to treatment assignment or clinical outcomes. For the external cohort, institutional review boards at each site approved the trial, and patients provided written, informed consent. The study was approved by the Food and Drug Administration (NCT03000270).

94

### 95 Echocardiography Image Acquisition, Preprocessing, and Semantic Segmentation

96 Echocardiograms from A4C, A3C, and A2C were utilized in the present studies 97 for both the internal and external validation data analysis. Patients and participants 98 required at least two of the three views to be present to be included in the current study 99 (see Materials and Methods, section Study Population). 2D echocardiograms were 100 preprocessed from video formats to DICOM using Sante DICOM Viewer Pro (SanteSoft, 101 Nicosia, Cyprus, Greece). DICOM files containing doppler data, dual ultrasound 102 regions, or other with limited technical views were discarded. A4C, A3C, and A2C multi-103 beat echocardiogram DICOM files were manually selected. Using echocv (30) (i.e., a 104 semantic segmentation algorithm that automatically defines regions of the heart in 105 echocardiography images through convolutional neural networks (CNNs)) were 106 segmented the region of the left ventricle (LV) in the A4C, A3C, and A2C views.

107 Compared to the published version of the algorithm, we modified echocv to be 108 executed using Python 3.2 and leveraged TensorFlow 1.15.0 with GPU support, 109 alongside CUDA 10.0. The segmented images were also uniformly resized to a fixed 110 shape of 1024 by 1024 to ensure consistency across various image sources. Otherwise

the use of algorithm and its validation has previously been published, specifically for predicting LV remodeling in parasternal long axis echocardiograms (31).Using the semantic segmentation algorithm, a binary mask representing the region of interest (ROI) within the A4C, A3C, and A2C views was achieved (**Figure S1A**). The ROI for each of the three views was then processed to obtained radiomics/ultrasomics-based information.

- 117
- 118 Texture-based Feature Extraction

119 Echocardiography ultrasomics were extracted in Python (v3.7.13) using 120 pyradiomics (v3.0.1) (32), SimpleITK (v2.2.0) (33), pywavelets (v1.3.0), and numpy 121 (v1.21.5) for both the internal and external validation sets. We have previously 122 published using this methodology on the LV (31). Briefly, feature extraction was 123 performed for the 2D ROI using featureextractor() from pyradiomics. Default parameters 124 for extraction, binwidth, resampled pixel spacing, interpolator, label definition, were 125 applied. In total, first-order (n=18), shape (n=9), and texture-based (n=73) features were 126 extracted for each of the echocardiography views (i.e., A4C, A3C, and A2C) (Figure 127 S1B).

128

### 129 Topological Data Analysis (TDA)

The online tool TDAView (34) was used for phenogroup cluster of AMI patients in the internal validation set. TDAView utilizes the Mapper algorithm for TDA. A 1D Mapper filter was applied using Euclidean distance. Number of intervals was defined as 10, with 5 bins. To reduce the overlap between clusters, a 5% overlap was defined. The number

134	of clusters was not fixed. Based on the parameters used in TDAView, three clusters
135	were generated, labeled as Cluster A (n=62), B (n=43), and C (n=50).

136

### 137 Supervised Machine Learning Classifier

138 BigML (https://bigml.com. BigML, Inc. Corvallis, Oregon, USA) was utilized for 139 supervised machine learning and to develop a classifier for prediction of patients in 140 Cluster A, B, and C. Weights were applied to Cluster A (weight=1), Cluster B 141 (weight=1.189), and Cluster C (weight=1.023) to address class imbalance. Through the 142 OptiML application (i.e., a supervised machine learning algorithm that compares 143 generated ensembles, deep neural networks, and logistic regression algorithms) 10-fold 144 cross validation was performed and prediction of Cluster A, B, and C phenogroups was 145 performed using only ultrasomics features. Once the model was developed, batch 146 prediction was performed on the external validation set (n=42 participants) to assign 147 phenogroup information.

148

149 Data Availability

150 All code is made freely available on our GitHub repository 151 <u>https://github.com/qahathaway/AMI\_Phenogroups</u>. All data is available by reasonable 152 request.

153

154 Statistics

GraphPad Prism (v10.1.1) and R (v4.1.0) were used for statistical analyses. The
Shapiro-Wilk test assessed normality. In normally distributed data with continuous

157 variables, a two-sided Student's t-test was applied. In non-Gaussian distributed data, 158 the Mann-Whitney test was used. When assessing more than one group of continuous 159 variables, a one-way analysis of variance (ANOVA) was applied. A Dunnett's multiple 160 comparisons test was used for multiple comparisons in the one-way ANOVA. When 161 assessing more than one group of categorical variables, a non-parametric Kruskal-162 Wallis test was applied with multiple comparisons testing.

163 Receiver operating characteristics (ROC) area under the curve (AUC) was 164 created using the BigML platform, utilizing 10-fold cross validation. A Kaplan-Meier 165 curve was generated using the R packages survival (v3.4-0) (35) and survminer 166 (v0.4.9). Stratification of events, assessed as patients at risk for mortality at one year, 167 was performed over 50-day increments for patients in Cluster A, Cluster B, and Cluster 168 C. The *P*-value was calculated using the log-rank test in R. Using the survival package, 169 a Cox Proportional Hazard model (CoxPH) for time-to-event analyses of mortality at one 170 year was assessed. A risk score was generated with the A) GRACE 2.0 score alone, B) 171 GRACE + Cluster A, C) GRACE + LV global longitudinal strain, and D) using all three 172 variables through CoxPH regression. A probability score (i.e., ranging from 0 to 1) for 173 predicting outcomes was generated using the predictRisk function of the riskRegression 174 (v2022.11.28) package in R. The concordance index (C-statistic) was calculated using 175 the pec (v2022.05.04) package in R (36).

### 176 Results

### 177 Study Overview

178 The current study utilizes an internal validation group of acute myocardial 179 infarction (AMI) patients (n=155) presenting with non-ST-elevation myocardial infarction 180 (NSTEMI) and ST-elevation myocardial infarction (STEMI). Apical 4-chamber (A4C), 181 apical 3-chamber (A3C), and apical 2-chamber (A2C) views were utilized (Figure 2A). 182 Using echocardiography-derived ultrasomics, phenogroups were labeled through TDA 183 and applied to the prediction of clinical outcomes, such as time-to-event mortality 184 (Figure 2B). A supervised machine learning algorithm was further used to characterize 185 which radiomics features are important in prediction of the phenogroups and generation 186 of risk prediction score. We then evaluated the incremental value of the phenogroups 187 using the internal validation group and explored how assigned phenogroup labels 188 contributed to predicting CMR findings in the external validation group (Figure 2C).

189

### 190 Patient Demographics and Functional Parameters – Internal Validation

191 Demographic features for patients in the internal validation study presenting with 192 NSTEMI (n=63) and STEMI (n=92) were assessed (**Table 1**). Patients presenting with 193 STEMI were more likely to have a history of congestive heart failure (CHF) (20.65% vs. 194 1.59%, P=0.0004) and higher Global Registry of Acute Coronary Events (GRACE) 195 Score (120.63 vs. 107.92, P=0.0184), compared to NSTEMI patients, respectively. 196 Patients presenting with NSTEMI were more likely to have a history of coronary artery 197 disease (CAD) (52.38% vs. 19.57%, P<0.0001), chonic kindey disease (CKD) (23.81%) 198 vs. 10.87%, P=0.0315), and stroke (17.46% vs. 6.52%, P=0.0324), compared to STEMI

patients, respectively. When comparing the groups based on type of AMI, there were no
differences in outcomes, including major adverse cardiac events (MACE) at 30 days
(P=0.3803), cardiovascular death at 1 year (P=0.8910), and all-cause mortality at 1 year
(0.9502).

203 Echocardiographic functional features for patients in the internal validation study 204 presenting with NSTEMI (n=63) and STEMI (n=92) were assessed (Table 2). Patients 205 presenting with STEMI were more likely to have a LV ejection fraction (48% vs. 53%, P=0.0087) and left atrial end-systolic volume index (23 mL/m<sup>2</sup> vs. 29 mL/m<sup>2</sup>, P=0.0024). 206 207 compared to NSTEMI patients, respectively. Further the LV wall motion score index (2 208 vs. 1.7, P=0.0072) and LV global longitudinal strain (-11.86 vs. -14.1, P=0.0015) 209 indicated greater wall motion abnormalities in STEMI compared to NSTEMI patients, 210 respectively.

211

### 212 Phenogroup Clustering through Topological Data Analysis (TDA)

213 Ultrasomics features were collected from the following echocardiography views: 214 A4C, A3C, and A2C (Figure 1A-B). To understand if these features have value in 215 predicting outcomes in patients presenting with AMI, ultrasomics features alone were 216 evaluated using a TDA clustering algorithm that employed Mapper. Using the online tool 217 TDAView, three phenogroups were identified: Cluster A (n=62), Cluster B (n=43), and 218 Cluster C (n=50) (Figure 2). Of these phenogroups, Cluster A and Cluster B are 219 illustrated to be more homogenous in their connectivity within groups, whereas Cluster 220 C is illustrated to represent a more heterogenous compilation of patients.

221 Assessing the differences between these clusters, Cluster A contains more 222 patients with a prior history of CHF (22.58% vs. 8%, P=0.0397), compared to Cluster C 223 (Table 3). Further, the Cluster A phenogroup has a higher risk of all-cause mortality at 1 224 year (19.35% vs. 4%, P=0.0308), compared to Cluster C. The data in Table 2 highlight 225 how the Cluster A represents a "high-risk" phenogroup, whereas Cluster B can be seen 226 "intermediate-risk" "low-risk". When as and Cluster C as assessing the 227 echocardiographic functional parameters (**Table 4**), Cluster A had a reduced LV ejection 228 fraction (45 vs. 53, P=0.0040) and LV global longitudinal strain (-11.88 vs. 13.87, 229 P=0.0273) compared to Cluster C, respectively.

230

### 231 Supervised Machine Learning Classifier for Phenogroups

232 То establish individual patient-level probabilities to belong to specific 233 phenogroups, a supervised machine learning classifier was developed using the online 234 tool BigML with their OptiML application (i.e., mixed supervised model with 10-fold cross 235 validation) on the internal validation patients. Using only ultrasomics features, the 236 phenogroup labels were predicted for Cluster A (ROC AUC: 0.95), Cluster B (ROC AUC: 237 0.95), and Cluster C (ROC AUC: 0.92) (Figure 3A). When looking at the features 238 contributing to the model, there was a mix of texture-based features and first order 239 features (Figure 3B). Prediction probabilities were generated for the internal validation 240 dataset based on the supervised classifier; these probabilities were used in subsequent 241 analyses for risk prediction.

242

### 243 Outcome Prediction in the Internal and External Patient Groups

medRxiv preprint doi: https://doi.org/10.1101/2024.03.26.24304839; this version posted March 27, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

244 Using mortality at one year, survival analysis revealed that patients assigned to 245 Cluster A had a significant increase in mortality compared to Cluster C (log rank, 246 P=0.0489) (Figure 4A). We further wanted to further understand if the phenogroups, 247 represented by changes in ultrasomics, had incremental value when predicting 248 mortality. The concordance index was calculated for our four groups of variables: A) 249 GRACE 2.0 score alone, B) GRACE + Cluster A, C) GRACE + LV global longitudinal 250 strain, and D) using all three variables together (Figure 4B). We further illustrate that 251 the use of ultrasomics alone (Concordance: 0.74 vs. 0.70, P=0.0395), and in 252 combination with functional echocardiographic markers (Concordance: 0.81 vs. 0.70, 253 P<0.0001), can increase prediction of all-cause mortality beyond that of the GRACE 2.0 254 score, respectively.

255 The developed supervised model was further applied to the external participants 256 to assign phenogroup labels (i.e., Cluster A, B, and C). The batch prediction of the 257 external dataset (n=42 presenting with STEMI) labeled participants into Cluster A 258 (n=11), Cluster B (n=23), and Cluster C (n=8) (**Table 5**). Patients in Cluster A had a 259 higher percentage of LV identified as "at risk" (60% vs. 37%, P=0.04) at 5 days post AMI, compared to Cluster C. Moreover, patients in the Cluster A phenogroup had a 260 261 higher proportion of large infarcts (>10% of LV mass) at 30 days following AMI (0.91 vs. 262 0.25, P=0.007), when compared to Cluster C.

### 263 Discussion

264 Properties of pathological changes within the myocardial microstructure influence 265 ultrasound signal intensity distributions (31). Unlike information obtained indirectly (i.e., 266 clinical risk factors, ECG, and biomarkers), specific analyzable trends in ultrasound 267 texture information may have added insights into causal pathways that result in disease 268 and clinical presentation. Integrating myocardial texture analysis (i.e., ultrasomics) with 269 clinical data can provide a rich opportunity to develop machine learning models to 270 predict adverse cardiac events following AMI. To this end we provide a proof-of-concept 271 application of ultrasomics (i.e., cardiac ultrasound radiomics) in risk stratifying AMI 272 patients. Three AMI phenogroups were identified according to ultrasound texture 273 features with patients in phenogroup A having the worst prognosis. Phenogroup A 274 showed incremental and independent information over GRACE 2.0 for predicting 1-year 275 mortality after AMI. Using a cluster-then-predict framework we utilized an external hold 276 out dataset for phenogroup prediction in which phenogroup A had large proportion of 277 patients with moderate or large infarcts.

278 While classic supervised learning approaches require larger datasets, the 279 cluster-then-predict methodology has the advantage of reducing bias, such as 280 overfitting, when risk stratifying patients. Moreover this approach reduces prediction 281 errors (37) and shows robust performance with echo-related data (38-41). Radiomics, 282 deep learning features, 2D-echocardiography, demographic/clinical (e.g., age, sex, 283 race, BSA, BMI, comorbidities, family history, etc.), laboratory, and biomarker data can 284 further be added to incrementally increase the risk-stratification of these phenogroups. 285 Our group has previously utilized TDA to create patient similarity networks to identify

286 aortic stenosis (42), diastolic dysfunction (43-45), and heart failure (46,47). In aortic 287 stenosis, by creating patient phenogroups for mild and severe aortic stenosis, the "high-288 risk" severe aortic stenosis phenogroup was associated with increased risk of balloon 289 valvuloplasty, and valve replacement (42). Specifically, as shown in this study, the 290 phenotypic groups from TDA (or unsupervised machine learning, PCA clustering, etc.) 291 can serve as class labels for developing supervised algorithms. This technique, first 292 clustering and then predicting using supervised machine-learning models, can result in 293 stronger associations with clinical outcomes by increasing the number of events (i.e., 294 phenogroup clusters) and reduce class imbalance.

295 Current risk stratification tools for AMI, such as the GRACE Score, reduce 296 mortality rates compared to standard strategies (48,49) but, with the use of current AI 297 applications, it is possible to characterize more patients at-risk for morbidity and 298 mortality by combining information from clinical, laboratory, imaging, and other features. 299 Risk stratification tools can be benchmarked using AUC and C-Index as metrics, with 300 values ranging from 0.6-0.7 having limited clinical value, whereas those between 0.7-301 0.8, 0.8-0.9, and >0.9 considered to have fair, good, and excellent discrimination (50-302 52), respectively. The GRACE model has shown performances ranging from 0.65-0.8 303 (C-Index) (9), with our current study reporting a performance of 0.70, utilizing the 304 GRACE 2.0 score. We also showed how the C-Index improved when using ultrasomics 305 features (0.74) and in combination with LV functional parameters (0.81). As this is a pilot 306 study, future work should harness these non-clinical markers (such as ultrasomics and 307 LV functional information) in larger, multicenter studies to create new risk stratification 308 tools for the prediction of AMI.

medRxiv preprint doi: https://doi.org/10.1101/2024.03.26.24304839; this version posted March 27, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

309 We note several limitations to the current investigation. 1) The cohort sizes in the 310 internal and external validations sets are relatively small (n=155 and n=42, 311 respectively). While this patient groups are small, we highlight how the cluster-then-312 predict methodology is better adapted to smaller datasets and can help provide a 313 framework for other investigations where small cohort sizes are present (i.e., rare 314 diseases, underrepresented minorities, limited resources for data collection, etc.). 2) 315 The outcome of interest, all-cause mortality at 1 year, was only represented in 20 of 155 316 patients. Because of the low number of events, we used univariate analysis to screen 317 for features to provide in the adjusted model while avoid issues with overfitting in the 318 survival model. Nevertheless, we noted the incremental value of radiomics over 319 conventional scores like Grace 2.0 and several echocardiographic parameters like 320 ejection fraction, LV end-systolic volume and global longitudinal strain. Future work with 321 larger sample size and a greater number of events would allow develop of robust 322 multivariable models using radiomics, clinical and conventional echocardiographic 323 features. 3) The use of TDA, and other unsupervised learning approaches, can be 324 subjective in the number of clusters defined. In the current study, we highlight three 325 unique phenogroups. While we could have altered the parameters to include more or 326 less numbers of phenogroups, the main constraint on the Mapper algorithm that we wanted to maintain was a low percent overlap between groups (i.e., reducing the 327 328 similarities of phenogroups and ultimately providing clearer boundaries between those 329 with "high" and "low" risk).

330 In summary, we utilize an echocardiography-derived approach to measure 331 ultrasomics and identify phenogroups among patients presenting with AMI. Through

332 TDA, three distinct phenogroups (Clusters A, B, and C) were delineated, with Cluster A 333 representing a "high-risk" group, Cluster B an "intermediate-risk" group, and Cluster C a 334 "low-risk" group. These phenogroups demonstrated significant differences in clinical 335 outcomes, particularly in terms of all-cause mortality at 1 year. Logistic regression and 336 machine learning further validate the predictive power of these supervised 337 phenogroups, showing their potential utility in clinical risk stratification. Moreover, 338 application of the developed model to an external dataset highlighted the robustness of 339 these phenogroups in predicting cardiac magnetic resonance (CMR) findings such as 340 infarct size, providing valuable insights for personalized patient management and 341 prognostication in AMI.

### 342 Acknowledgments

- 343 None
- 344

### 345 Sources of Funding

- 346 This work was supported by: NSF: # 2125872 (PPS)
- 347

### 348 Disclosures

- 349 Dr. Sengupta is a consultant for RCE Technologies, Echo IQ. Dr. Yanamala is an
- advisor to Turnkey Learning, LLC and Turnkey Learning (P) Ltd, Pittsburgh, PA, USA.
- 351 All other authors have no reported disclosures relevant to the contents of this paper to

352 disclose.

- 353
- 354 Author Contributions
- 355

356

### 357 References

- Salari N, Morddarvanjoghi F, Abdolmaleki A et al. The global prevalence of myocardial infarction: a systematic review and meta-analysis. BMC Cardiovasc Disord 2023;23:206.
- Bishu KG, Lekoubou A, Kirkland E et al. Estimating the Economic Burden of
   Acute Myocardial Infarction in the US: 12 Year National Data. Am J Med Sci
   2020;359:257-265.
- Tsao CW, Aday AW, Almarzooq ZI et al. Heart Disease and Stroke Statistics—
   2022 Update: A Report From the American Heart Association. Circulation
   2022;145:e153-e639.
- Fox KAA, Dabbous OH, Goldberg RJ et al. Prediction of risk of death and
  myocardial infarction in the six months after presentation with acute coronary
  syndrome: prospective multinational observational study (GRACE). BMJ
  2006;333:1091.
- 3715.Eagle KA, Lim MJ, Dabbous OH et al. A Validated Prediction Model for All Forms372of Acute Coronary Syndrome. JAMA 2004;291:2727.
- Fox KA, Fitzgerald G, Puymirat E et al. Should patients with acute coronary
   disease be stratified for management according to their risk? Derivation, external
   validation and outcomes using the updated GRACE risk score. BMJ Open
   2014;4:e004425.
- Collet J-P, Thiele H, Barbato E et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent STsegment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal 2020;42:1289-1367.
- 383 8. Gulati M, Levy PD, Mukherjee D et al. 2021
- AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and
   Diagnosis of Chest Pain: Executive Summary: A Report of the American College
   of Cardiology/American Heart Association Joint Committee on Clinical Practice
   Guidelines. Circulation 2021;144:e336-e367.
- 388
  9. D'Ascenzo F, Biondi-Zoccai G, Moretti C et al. TIMI, GRACE and alternative risk
  389 scores in Acute Coronary Syndromes: a meta-analysis of 40 derivation studies
  390 on 216,552 patients and of 42 validation studies on 31,625 patients. Contemp
  391 Clin Trials 2012;33:507-14.
- 39210.Rajpurkar P, Chen E, Banerjee O, Topol EJ. AI in health and medicine. Nature393Medicine 2022;28:31-38.
- Koh D-M, Papanikolaou N, Bick U et al. Artificial intelligence and machine
  learning in cancer imaging. Communications Medicine 2022;2:133.
- 396 12. Gulshan V, Peng L, Coram M et al. Development and Validation of a Deep
   397 Learning Algorithm for Detection of Diabetic Retinopathy in Retinal Fundus
   398 Photographs. JAMA 2016;316:2402-2410.
- Huynh E, Hosny A, Guthier C et al. Artificial intelligence in radiation oncology. Nat
   Rev Clin Oncol 2020;17:771-781.

401 402	14.	McKinney SM, Sieniek M, Godbole V et al. International evaluation of an Al system for breast cancer screening. Nature 2020;577:89-94.
403 404 405	15.	Ardila D, Kiraly AP, Bharadwaj S et al. End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. Nat Med 2019:25:954-961
405 406 407	16.	Zhou D, Tian F, Tian X et al. Diagnostic evaluation of a deep learning model for optical diagnosis of colorectal capcer. Nat Commun 2020:11:2961
408 409	17.	Lambin P, Leijenaar RTH, Deist TM et al. Radiomics: the bridge between medical imaging and personalized medicine. Nature Reviews Clinical Oncology
410		2017;14:749-762.
411	18.	Cho H-h, Lee HY, Kim E et al. Radiomics-guided deep neural networks stratify
412		lung adenocarcinoma prognosis from CT scans. Communications Biology
413		2021;4:1286.
414	19.	Wang Y, Yue W, Li X et al. Comparison Study of Radiomics and Deep Learning-
415		Based Methods for Thyroid Nodules Classification Using Ultrasound Images.
416		IEEE Access 2020;8:52010-52017.
417	20.	Afshar P, Mohammadi A, Plataniotis KN, Oikonomou A, Benali H. From
418		Handcrafted to Deep-Learning-Based Cancer Radiomics: Challenges and
419		Opportunities. IEEE Signal Processing Magazine 2019;36:132-160.
420	21.	Hunter B, Chen M, Ratnakumar P et al. A radiomics-based decision support tool
421		improves lung cancer diagnosis in combination with the Herder score in large
422		lung nodules. EBioMedicine 2022;86:104344.
423	22.	Chazal F, Michel B. An Introduction to Topological Data Analysis: Fundamental
424		and Practical Aspects for Data Scientists. Front Artif Intell 2021;4:667963.
425	23.	Stone GW, Selker HP, Thiele H et al. Relationship Between Infarct Size and
426		Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized
427		Trials. J Am Coll Cardiol 2016;67:1674-83.
428	24.	Kapur NK, Alkhouli MA, DeMartini TJ et al. Unloading the Left Ventricle Before
429		Reperfusion in Patients With Anterior ST-Segment-Elevation Myocardial
430		Infarction. Circulation 2019;139:337-346.
431	25.	Thygesen K, Alpert JS, Jaffe AS et al. Third universal definition of myocardial
432		infarction. Eur Heart J 2012:33:2551-67.
433	26.	Akbar H, Foth C, Kahloon RA, Mountfort S. Acute ST-Elevation Myocardial
434	-	Infarction, StatPearls, Treasure Island (FL) ineligible companies, Disclosure:
435		Christopher Foth declares no relevant financial relationships with ineligible
436		companies. Disclosure: Rehan Kahloon declares no relevant financial
437		relationships with ineligible companies. Disclosure: Steven Mountfort declares no
438		relevant financial relationships with ineligible companies. 2024.
439	27.	Smith SW. Dodd KW. Henry TD. Dvorak DM. Pearce I A. Diagnosis of ST-
440		elevation myocardial infarction in the presence of left bundle branch block with
441		the ST-elevation to S-wave ratio in a modified Soarbossa rule. Ann Emerg Med
442		2012·60·766-76
443	28	Al-Hussaini A. Abdelaty A. Gulsin GS et al. Chronic infarct size after spontaneous
444	-01	coronary artery dissection: implications for pathophysiology and clinical
445		management. Fur Heart J 2020:41:2197-2205
		management Euritouro Eoco, metor Ecol

446 29. Krijanac G, Apostolovic S, Polovina M et al. Differences in left ventricular 447 myocardial function and infarct size in female patients with ST elevation 448 myocardial infarction and spontaneous coronary artery dissection. Front 449 Cardiovasc Med 2023;10:1280605. 450 30. Zhang J, Gajjala S, Agrawal P et al. Fully Automated Echocardiogram 451 Interpretation in Clinical Practice. Circulation 2018;138:1623-1635. 452 31. Hathaway QA, Yanamala N, Siva NK, Adjeroh DA, Hollander JM, Sengupta PP. 453 Ultrasonic Texture Features for Assessing Cardiac Remodeling and Dysfunction. 454 J Am Coll Cardiol 2022:80:2187-2201. 455 32. van Griethuysen JJM, Fedorov A, Parmar C et al. Computational Radiomics 456 System to Decode the Radiographic Phenotype. Cancer Res 2017;77:e104-457 e107. 458 33. Yaniv Z, Lowekamp BC, Johnson HJ, Beare R. SimpleITK Image-Analysis 459 Notebooks: a Collaborative Environment for Education and Reproducible 460 Research. Journal of Digital Imaging 2018;31:290-303. 461 34. Walsh K, Voineagu MA, Vafaee F, Voineagu I. TDAview: an online visualization 462 tool for topological data analysis. Bioinformatics 2020;36:4805-4809. 463 35. Therneau TM. A Package for Survival Analysis in R. 2022: R package version 3.4-464 0. 465 36. Mogensen UB, Ishwaran H, Gerds TA. Evaluating Random Forests for Survival 466 Analysis using Prediction Error Curves. J Stat Softw 2012;50:1-23. 467 37. Trivedi S, Pardos ZA, Heffernan NT. The utility of clustering in prediction tasks. 468 arXiv preprint arXiv:150906163 2015. 469 Kagiyama N, Shrestha S, Cho JS et al. A low-cost texture-based pipeline for 38. 470 predicting myocardial tissue remodeling and fibrosis using cardiac ultrasound. 471 EBioMedicine 2020;54:102726. 472 39. Tokodi M, Shrestha S, Bianco C et al. Interpatient similarities in cardiac function: 473 a platform for personalized cardiovascular medicine. Cardiovascular Imaging 474 2020;13:1119-1132. 475 Pandey A, Kagiyama N, Yanamala N et al. Deep-learning models for the 40. 476 echocardiographic assessment of diastolic dysfunction. Cardiovascular Imaging 477 2021;14:1887-1900. Sengupta PP, Shrestha S, Kagiyama N et al. A Machine-Learning Framework to 478 41. 479 Identify Distinct Phenotypes of Aortic Stenosis Severity. JACC Cardiovasc 480 Imaging 2021;14:1707-1720. 481 42. Casaclang-Verzosa G, Shrestha S, Khalil MJ et al. Network Tomography for 482 Understanding Phenotypic Presentations in Aortic Stenosis. JACC Cardiovasc 483 Imaging 2019;12:236-248. 484 43. Pandey A, Kagiyama N, Yanamala N et al. Deep-Learning Models for the 485 Echocardiographic Assessment of Diastolic Dysfunction. JACC Cardiovasc 486 Imaging 2021;14:1887-1900. 487 Shah R, Tokodi M, Jamthikar A et al. A Deep Patient-Similarity Learning 44. 488 Framework for the Assessment of Diastolic Dysfunction in Elderly Patients. Eur 489 Heart J Cardiovasc Imaging 2024.

- 490 45. Tokodi M, Shrestha S, Bianco C et al. Interpatient Similarities in Cardiac
  491 Function: A Platform for Personalized Cardiovascular Medicine. JACC
  492 Cardiovasc Imaging 2020;13:1119-1132.
- 493 46. Cho JS, Shrestha S, Kagiyama N et al. A Network-Based "Phenomics" Approach
  494 for Discovering Patient Subtypes From High-Throughput Cardiac Imaging Data.
  495 JACC Cardiovasc Imaging 2020;13:1655-1670.
- 496
  47. Patel HB, Yanamala N, Patel B et al. Electrocardiogram-Based Machine Learning
  497
  498
  498
  498
  498
  498
  499
  490
  490
  490
  490
  490
  491
  492
  493
  494
  494
  495
  495
  496
  496
  497
  498
  498
  498
  499
  498
  499
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
- 48. Hall M, Bebb OJ, Dondo TB et al. Guideline-indicated treatments and
  diagnostics, GRACE risk score, and survival for non-ST elevation myocardial
  infarction. Eur Heart J 2018;39:3798-3806.
- 49. van der Sangen NMR, Azzahhafi J, Chan Pin Yin D et al. External validation of
  the GRACE risk score and the risk-treatment paradox in patients with acute
  coronary syndrome. Open Heart 2022;9.
- 50650.Ohman EM, Granger CB, Harrington RA, Lee KL. Risk stratification and507therapeutic decision making in acute coronary syndromes. JAMA 2000;284:876-5088.
- 509 51. Shann F. Are we doing a good job: PRISM, PIM and all that. Intensive Care Med 2002;28:105-7.
- 511 52. Solomon LJ. Mortality risk prediction models: Methods of assessing
  512 discrimination and calibration and what they mean. South Afr J Crit Care
  513 2022;38.
- 514

515

### 516 **Tables and Table Legends**

### 517 Table 1

Internal Validation - Patient Demographics Stratified by Acute Myocardial Infarction (AMI)					
Variable	NSTEMI (n=63)	STEMI (n=92)	P-Value		
Age (years)	68.03 (66.48-69.58)	65.47 (64.04-66.9)	0.28		
Sex/Gender (Male)	40 (63.49%)	70 (76.09%)	0.09		
Race/Ethnicity Caucasian Asian American Hispanic American Black/African American	24 (38.1%) 8 (12.7%) 14 (22.22%) 6 (9.52%)	37 (40.22%) 22 (23.91%) 14 (15.22%) 8 (8.7%)	0.79 0.08 0.27 0.86		
BMI (kg/m²)	27.82 (27.09-28.55)	28.43 (27.42-29.44)	0.67		
Systolic Blood Pressure (mmHg)	143 (140-146)	143 (140-147)	0.96		
Diastolic Blood Pressure (mmHg)	74 (72-75)	80 (78-82)	0.05		
Heart Rate (per minute)	84 (81-86)	85 (83-87)	0.66		
Cardiac Arrest (at admission)	0 (0%)	4 (4.35%)	0.09		
Troponin Elevation (at admission)	63 (100%)	89 (96.74%)	0.15		
Smoking History Current Former	11 (17.46%) 18 (28.57%)	18 (19.57%) 22 (24.18%)	0.74 0.54		
History of CHF	1 (1.59%)	19 (20.65%)	*0.0004		
History of COPD	5 (7.94%)	2 (2.17%)	0.09		
History of CAD	33 (52.38%)	18 (19.57%)	*<0.0001		
History of CKD	15 (23.81%)	10 (10.87%)	*0.03		
History of Diabetes Mellitus	35 (55.56%)	39 (42.39%)	0.11		
History of Hyperlipidemia	38 (60.32%)	51 (55.43%)	0.55		
Prior Myocardial Infarction	12 (19.05%)	13 (14.29%)	0.43		
Prior Percutaneous Intervention	22 (34.92%)	25 (27.17%)	0.31		
Prior Coronary Artery Bypass Graft	7 (11.11%)	7 (7.61%)	0.46		
Prior Stroke	11 (17.46%)	6 (6.52%)	*0.03		
GRACE Score	107.92 (105.04-110.8)	120.63 (116.97-124.28)	*0.02		
MACE at 30 Days	6 (9.52%)	13 (14.29%)	0.38		
Cardiovascular Death - 1 year	5 (8.06%)	8 (8.7%)	0.89		
All Cause Mortality - 1 year	8 (12.70%)	12 (13.04%)	0.95		

518

### 519 **Table 1: Patient Demographics of the Internal Validation Group Stratified by Acute**

520 Myocardial Infarction (AMI). Patients presenting with non-ST-elevation myocardial

521 infarction (NSTEMI, n=63) and ST-elevation myocardial infarction (STEMI, n=92). The

522 Shapiro-Wilk test assessed normality. In normally distributed data with continuous 523 variables, a two-sided Student's t-test was applied. In non-Gaussian distributed data, 524 the Mann-Whitney test was used. Data are presented as the percent (%) of total or the 525 95% confidence interval, where applicable. Data are considered statistically significant if 526 P≤0.05, denoted by \*. BMI = body mass index, CHF = congestive heart failure, COPD = 527 chronic obstructive pulmonary disease, CAD = coronary artery disease, CKD = chronic 528 kidney disease, GRACE = Global Registry of Acute Coronary Events, MACE = major 529 adverse cardiac events.

### 530 Table 2

Internal Validation - Patient Cardiac Function Stratified by Acute Myocardial Infarction (AMI)				
Variable	NSTEMI (n=63)	STEMI (n=92)	P-Value	
Left Ventricular Internal Diameter - End Diastole (mm)	46 (45-47)	47 (45-49)	0.38	
Left Ventricular Internal Diameter - End Systole (mm)	34 (32-36)	37 (35-39)	0.07	
Left Ventricular Mass Index (g/m <sup>2</sup> )	87 (81-93)	92 (85-98)	0.35	
Left Ventricular End-diastole Volume (mL)	94 (86-103)	106 (99-113)	0.06	
Left Ventricular End-systole Volume (mL)	47 (40-53)	57 (51-62)	*0.03	
Left Ventricular Ejection Fraction (%)	53 (50-56)	48 (45-50)	*0.009	
Left Ventricular Wall Motion Score Index	1.7 (1.56-1.83)	2 (1.9-2.11)	*0.007	
Left Ventricular Global Longitudinal Strain (%)	-14.1 (-15.07 13.12)	-11.86 (-12.64 11.08)	*0.002	
Left Ventricular Outflow Tract Stroke Volume (mL)	61 (56-66)	55 (51-59)	0.12	
e' Septal	5.90 (5.47-6.33)	6.04 (5.64-6.43)	0.64	
e' Lateral	8.26 (7.51-9.02)	7.79 (7.26-8.32)	0.95	
Mitral Valve E Wave (cm/s)	85 (78-91)	83 (77-89)	0.81	
MV-A (cm/s)	85 (79-91)	79 (74-84)	0.21	
E/A Ratio	1.06 (0.94-1.18)	1.05 (0.96-1.14)	0.92	
E/e' Septal	15.70 (13.71-17.69)	15.06 (13.66-16.45)	0.64	
E/e' Lateral	11.57 (10.19-12.94)	11.63 (10.44-12.82)	0.95	
Left Atrial End-systolic Volume Index (mL/m <sup>2</sup> )	29 (26-31)	23 (21-25)	*0.002	

531

532 Table 2: Patient Cardiac Function of the Internal Validation Group Stratified by 533 Acute Myocardial Infarction (AMI). Patients presenting with non-ST-elevation 534 myocardial infarction (NSTEMI, n=63) and ST-elevation myocardial infarction (STEMI, 535 n=92). The Shapiro-Wilk test assessed normality. In normally distributed data with 536 continuous variables, a two-sided Student's t-test was applied. In non-Gaussian 537 distributed data, the Mann-Whitney test was used. Data are presented as the percent 538 (%) of total or the 95% confidence interval, where applicable. Data are considered 539 statistically significant if P≤0.05, denoted by \*.

### 540 Table 3

Internal Validation - Patient Demographics in Predicted Ultrasomics Phenogroups				
Variable	Cluster A (High Risk) (n=62)	Cluster B (n=43)	Cluster C (Low Risk) (n=50)	P- Value
Age (years)	66.74 (62.98-70.51)	66.88 (62.34- 71.43)	65.9 (62.03-69.77)	0.94
Sex/Gender (Male)	44 (70.97%)	31 (72.09%)	35 (70%)	0.98
Race/Ethnicity				
Caucasian	24 (38.71%)	16 (37.21%)	21 (42%)	0.89
Asian American	12 (19.35%)	8 (18.6%)	10 (20%)	0.99
Hispanic American	9 (14.52%)	9 (20.93%)	10 (20%)	0.64
Black/African American	5 (8.065%)	4 (9.302%)	5 (10%)	0.94
BMI (kg/m²)	29.01 (26.08-31.93)	28.9 (26.91- 30.89)	26.56 (24.68-28.43)	0.28
Systolic Blood Pressure (mmHg)	140 (132-149)	145 (135-155)	145 (136-155)	0.65
Diastolic Blood Pressure (mmHg)	78 (73-84)	77 (71-84)	76 (71-80)	0.72
Heart Rate (per minute)	86 (81-92)	85 (78-93)	81 (76-87)	0.47
Cardiac Arrest (at admission)	2 (3.226%)	1 (2.326%)	1 (2%)	0.92
Troponin Elevation (at admission)	61 (98.39%)	43 (100%)	48 (96%)	0.37
STEMI (at admission)	36 (58.06%)	26 (60.47%)	30 (60%)	0.96
Smoking History	, <i>, , , , , , , , , , , , , , , , , , </i>			
Current	16 (25.81%)	11 (25.58%)	13 (26.53%)	0.99
Former	10 (16.13%)	6 (13.95%)	13 (26%)	0.27
History of CHF	14 (22.58%)*	2 (4.651%)	4 (8%)	*0.01
History of COPD	1 (1.613%)	4 (9.302%)	2 (4%)	0.17
History of CAD	21 (33.87%)	18 (41.86%)	12 (24%)	0.19
History of CKD	10 (16.13%)	5 (11.63%)	10 (20%)	0.55
History of Diabetes Mellitus	30 (48.39%)	19 (44.19%)	25 (50%)	0.85
History of Hyperlipidemia	34 (54.84%)	25 (58.14%)	30 (60%)	0.86
Prior Myocardial Infarction	8 (12.9%)	10 (23.26%)	7 (14.29%)	0.34
Prior Percutaneous Intervention	5 (8.065%)	5 (11.63%)	4 (8%)	0.67
Prior Coronary Artery Bypass Graft	21 (33.87%)	13 (30.23%)	13 (26%)	0.79
Prior Stroke	6 (9.677%)	4 (9.302%)	7 (14%)	0.71
GRACE Score	118.1 (109.1-127.2)	114.5 (104.8- 124.3)	112.8 (103.9-121.8)	0.69
MACE at 30 Days	7 (11.29%)	5 (11.63%)	7 (14.29%)	0.88
Cardiovascular Death - 1 vear	8 (13.11%)	4 (9.302%)	1 (2%)	0.11
All Cause Mortality - 1 year	12 (19.35%)*	6 (13.95%)	2 (4%)	*0.04

541

542 Table 3: Patient Demographics of the Internal Validation Group for Predicted

543 Ultrasomics Phenogroups. Using only the ultrasomics features from the A4C, A3C,

544 and A2C echocardiogram views, patients were clustered into phenogroups. Cluster A 545 "high-risk" (n=62), Cluster B "intermediate-risk" (n=43), and Cluster C "low-risk" (n=50) 546 using topological data analysis (TDA). A one-way analysis of variance (ANOVA) was 547 applied for continuous variables and a Dunnett's multiple comparisons test was used for 548 multiple comparisons. For categorical data, a non-parametric Kruskal-Wallis test was 549 applied with multiple comparisons testing. Data are presented as the percent (%) of 550 total or the 95% confidence interval, where applicable. Data are considered statistically 551 significant if  $P \le 0.05$ , denoted by \*. BMI = body mass index, CHF = congestive heart 552 failure, COPD = chronic obstructive pulmonary disease, CAD = coronary artery disease, 553 CKD = chronic kidney disease, STEMI = ST-elevation myocardial infarction, GRACE = 554 Global Registry of Acute Coronary Events, MACE = major adverse cardiac events.

### 555 **Table 4**

Internal Validation - Patient Cardiac Function in Predicted Ultrasomics Phenogroups					
Variable	Cluster A (High Risk) (n=62)	Cluster B (n=43)	Cluster C (Low Risk) (n=50)	P- Value	
Left Ventricular Internal Diameter - End Diastole (mm)	48 (46-50)	46 (43-49)	45 (43-47)	0.17	
Left Ventricular Internal Diameter - End Systole (mm)	37 (35-40)*	35 (31-38)	33 (31-36)	*0.04	
Left Ventricular Mass Index (g/m <sup>2</sup> )	92 (84-99)	85 (76-93)	91 (81-101)	0.53	
Left Ventricular End-diastole Volume (mL)	103 (92-113)	108 (95-120)	95 (86-104)	0.27	
Left Ventricular End-systole Volume (mL)	58 (50-66)*	52 (42-62)	46 (40-53)	0.07	
Left Ventricular Ejection Fraction (%)	45 (41-49)*	54 (50-58)	53 (50-56)	*0.001	
Left Ventricular Wall Motion Score Index	2.00 (1.83-2.17)	1.80 (1.51- 2.10)	1.78 (1.61-1.96)	0.18	
Left Ventricular Global Longitudinal Strain (%)	-11.88 (-12.99 10.78)*	-13.1 (-14.55 11.66)	-13.87 (-15.03 12.72)	*0.04	
Left Ventricular Outflow Tract Stroke Volume (mL)	53 (48-59)*	57 (49-64)	64 (57-71)	*0.04	
e' Septal	5.48 (5.04-5.91)*	6.12 (5.54- 6.69)	6.50 (5.86-7.15)	*0.02	
e' Lateral	7.56 (6.85-8.27)	8.54 (7.64- 9.44)	8.03 (7.09-8.97)	0.25	
Mitral Valve E Wave (cm/s)	82 (75-90)	83 (72-93)	87 (78-95)	0.74	
MV-A (cm/s)	81 (74-89)	79 (69-88)	86 (77-94)	0.52	
E/A Ratio	1.06 (0.928-1.19)	1.05 (0.899- 1.21)	1.06 (0.886-1.22)	0.99	
E/e' Septal	16.51 (14.45-18.58)	14.64 (11.6- 17.67)	14.28 (12.43-16.12)	0.30	
E/e' Lateral	12.10 (10.48-13.72)	10.91 (8.86- 12.96)	11.58 (9.83-13.34)	0.63	
Left Atrial End-systolic Volume Index (mL/m <sup>2</sup> )	26 (24-29)	23 (20-26)	25 (21-29)	0.39	

556

Table 4: Patient Cardiac Function of the Internal Validation Group for Predicted
Ultrasomics Phenogroups. Using only the ultrasomics features from the A4C, A3C,
and A2C echocardiogram views, patients were clustered into phenogroups. Cluster A
"high-risk" (n=62), Cluster B "intermediate-risk" (n=43), and Cluster C "low-risk" (n=50)
using topological data analysis (TDA). A one-way analysis of variance (ANOVA) was
applied for continuous variables and a Dunnett's multiple comparisons test was used for

563 multiple comparisons. For categorical data, a non-parametric Kruskal-Wallis test was 564 applied with multiple comparisons testing. Data are presented as the percent (%) of 565 total or the 95% confidence interval, where applicable. Data are considered statistically 566 significant if P $\leq$ 0.05, denoted by \*.

### 567 **Table 5**

External Validation - Patient Demographics in Predicted Ultrasomics Phenogroups				
Variable	Cluster A (High Risk) (n=11)	Cluster B (n=23)	Cluster C (Low Risk) (n=8)	P- Value
Age (years)	56.82 (48.07-65.57)	58.26 (53.72- 62.8)	62.88 (54.99-70.76)	0.48
Sex/Gender (Male)	9 (81.82%)	18 (78.26%)	5 (62.5%)	0.60
Race/Ethnicity Caucasian Asian American Hispanic American Black/African American	8 (72.73%) 1 (9.091%) 0 (0%) 1 (9.09%)	17 (73.91%) 3 (13.04%) 1 (4.545%) 3 (13.04%)	6 (75%) 0 (0%) 0 (0%) 2 (25%)	0.99 0.58 0.66 0.62
BMI (kg/m²)	30.08 (25.73-34.42)	31.61 (27.35- 35.88)	25.61 (21.55-29.67)	0.23
Systolic Blood Pressure (mmHg)	148 (129-167)	158 (143-173)	144 (132-157)	0.44
Diastolic Blood Pressure (mmHg)	93 (81-104)	91 (84-99)	87 (75-99)	0.71
Heart Rate (per minute)	85 (77-93)	91 (81-101)	81 (66-96)	0.45
Left Ventricular Ejection Fraction (%)	36 (27-45)	37 (31-43)	44 (37-51)	0.41
Mitral Valve E Wave (cm/s)	74 (58-91)	77 (69-0.85)	74 (60-89)	0.93
Mitral Valve A Wave (cm/s)	72 (62-83)	69 (59-78)	74 (64-85)	0.71
E/A Ratio	1.07 (0.78-1.37)	1.20 (0.98-1.42)	1.02 (0.79-1.24)	0.55
History of COPD	0 (0%)	0 (0%)	0 (0%)	0.99
History of CAD	1 (9.091%)	1 (4.348%)	1 (12.5%)	0.73
History of CKD	0 (0%)	0 (0%)	0 (0%)	0.99
History of Diabetes Mellitus	3 (27.27%)	4 (17.39%)	0 (0%)	0.30
History of Hyperlipidemia	7 (63.64%)	9 (39.13%)	4 (50%)	0.42
Prior Stroke	1 (9.091%)	0 (0%)	0 (0%)	0.25
MACE - 30 Days	0 (0%)	2 (8.696%)	0 (0%)	0.44
Cardiovascular Death - 30 Days	0 (0%)	0 (0%)	0 (0%)	0.99
All Cause Mortality - 30 Days	0 (0%)	0 (0%)	0 (0%)	0.99
Infarct Size (%) of Area at Risk - 5 Days	60 (52-68)*	46 (37-56)	37 (18-56)	0.06
Acute Volume of Infarct Size (mL) - 5 Days	43 (32-54)	31 (20-42)	21 (-4.12-46)	0.17
Acute Infarct Size (%) of LV Mass - 5 Days	23 (17-29)	17 (11-23)	12 (-0.53-25)	0.24
Acute Infarct Size >10% of LV Mass - 5 Days	9 (82%)	14 (61%)	3 (38%)	0.07
Acute Volume of Infarct Size (mL) - 30 Days	28 (21-36)	23 (14-32)	14 (-3.10-31)	0.25
Acute Infarct Size (%) of LV Mass - 30 Days	18 (13-22)	14 (8.73-19)	9.23 (-1.31-20)	0.27
Acute Infarct Size >10% of LV Mass - 30 Days	10 (91%)	11 (48%)	2 (25%)	*0.008

568

569 Table 5: Patient Demographics of the External Validation Group for Predicted 570 Ultrasomics Phenogroups. Using the supervised machine learning classifier 571 developed on the internal validation cohort, class labels were generated for the external 572 hold out dataset (i.e., the prospective, multicenter, randomized DTU-STEMI pilot trial 573 dataset) using batch prediction in BigML. Labels were applied based solely on 574 ultrasomics features from the A4C, A3C, and A2C echocardiogram views. A one-way 575 analysis of variance (ANOVA) was applied for continuous variables and a Dunnett's 576 multiple comparisons test was used for multiple comparisons. For categorical data, a 577 non-parametric Kruskal-Wallis test was applied with multiple comparisons testing. Data 578 are considered statistically significant if P≤0.05, denoted by \*. BMI = body mass index, 579 CHF = congestive heart failure, COPD = chronic obstructive pulmonary disease, CAD = 580 coronary artery disease, CKD = chronic kidney disease, MACE = major adverse cardiac 581 events, LV = left ventricular.

### 582 Figure and Figure Legends

583 Figure 1: Study Design and Overview. (A) The internal validation patient cohort 584 included patients with presenting with non-ST-elevation myocardial infarction (NSTEMI, 585 n=63) and ST-elevation myocardial infarction (STEMI, n=92) who underwent 586 echocardiography with views of the Apical 2-Chamber (A2C), Apical 3-Chamber (A3C), 587 and Apical 4-Chamber (A4C). (B) Ultrasomics features were extracted using echocy 588 and pyradiomics (v3.0.1). TDAView was used to cluster patients into three 589 phenogroups: Cluster A, Cluster B, and Cluster C. The identified phenogroups were 590 used to develop individual patient predicted probability of cluster assignment using a 591 supervised machine learning classifier. (C) The generated probabilities from the 592 supervised classifier were used to predict mortality and illustrate the incremental value 593 of ultrasomics features over GRACE 2.0. Ultrasomics features were also extracted from 594 the external validation group and applied to the supervised machine learning classifier 595 to produce class labels (i.e., Cluster A, B, and C). The external validation phenogroups 596 were used to predict findings on cardiac magnetic resonance, including acute infarct 597 size.

### 598 Figure 2: Topological Data Analysis (TDA) Clustering of Ultrasomics Features.

- 599 Using TDAView a 1D Mapper filter was applied using Euclidean distance. Number of
- 600 intervals was defined as 10, with 5 bins. To reduce the overlap between clusters, a 5%
- 601 overlap was defined. Individual nodes are represented as red circles, with the number
- 602 next to the node corresponding to the number of patients included in the node. Cluster A
- 603 (n=62), Cluster B (n=43), and Cluster C (n=50).

Figure 3: Supervised Machine Learning Classifier. (A) Ultrasomics features, as well as the class label for the topological data analysis (TDA)-defined phenogroups, were assessed using BigML and OptiML through 10-fold cross validation in the internal validation data. (B) The top five features contributing to model development for the supervised machine learning classifier.

### 609 Figure 4: Performance of Phenogroups in Assessing All-Cause Mortality. (A)

- 610 Kaplan Meyer curve and stratified risk categories for patients in phenogroups Cluster A,
- 611 Cluster B, and Cluster C. (B) Time-to-event Concordance Index (C-Index) for groups A)
- 612 GRACE 2.0 score alone, B) GRACE + Cluster A, C) GRACE + left ventricular global
- 613 longitudinal strain (GLS), and D) using all three variables through CoxPH regression.
- 614 (C) Incremental value of ultrasomics features (i.e., Cluster A) in predicting all-cause
- 615 mortality. GRACE = Global Registry of Acute Coronary Events.

# A) Image



# raction ш 0 **B** Ц



A4C A3C A2C (n=122) (n=142) (n=155)







# **Combined TDA/Supervised Machine Learning**

## Ultrasomics









## Shape-based (n=9)

(e.g.) Mean Median Range

(e.g.) Perimeter Area Elongation

## Texture-based (n=73)



GLCM GLCM GLRLM GLSZM GLSZM GLSZM

# **C)**Analysis and Validation

## **Prediction Probabilities**



## External

## Predict Large Infarct



# Cluster A 25

medRxiv preprint doi: https://doi.org/10.1101/2024.03.26.24304839; this version posted March 27, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.





## B

reprint doi: https://doi.org/10.1101/2024.03.26.24304839; this version posted March 27, 2024. The copyright holder for this preprint was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

### A3C\_Original\_Firstorder\_RobustMeanAbsoluteDeviation

## A2C\_Original\_GLRLM\_HighGrayLevelRunEmphasis -





trata	Cluster C - 50 (100) Cluster B - 43 (100) Cluster A - 62 (100)	50 (100) 42 (98) 54 (87)	
S	Ó	73	

Time in days

dan 0.75-0.70 -C U

0.65

![](_page_40_Figure_6.jpeg)

![](_page_40_Figure_7.jpeg)

## A2C

Α

![](_page_41_Picture_1.jpeg)

![](_page_41_Picture_2.jpeg)

![](_page_41_Picture_3.jpeg)

![](_page_41_Picture_4.jpeg)

![](_page_41_Picture_5.jpeg)

![](_page_41_Picture_6.jpeg)

# <u>1st order (n=18)</u>

![](_page_41_Picture_9.jpeg)

(e.g.) Mean Median Range

![](_page_41_Picture_11.jpeg)

![](_page_41_Picture_12.jpeg)

![](_page_41_Picture_13.jpeg)

## <u>Shape-based (n=9)</u>

![](_page_41_Picture_15.jpeg)

(e.g.) Perimeter Area Elongation

## <u>Texture-based (n=73)</u>

GLCM GLCM GLRLM GLSZM GLSZM